UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000033357 |
|---|---|
| Receipt number | R000038024 |
| Scientific Title | FORTUNA(Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients undergoing Transcatheter Aortic Valve Replacement) |
| Date of disclosure of the study information | 2018/09/01 |
| Last modified on | 2020/01/14 12:39:08 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
FORTUNA(Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients undergoing Transcatheter Aortic Valve Replacement)
Acronym
FORTUNA
Scientific Title
FORTUNA(Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients undergoing Transcatheter Aortic Valve Replacement)
Scientific Title:Acronym
FORTUNA
Region
| Japan |
Condition
Condition
severe aortic stenosis
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
It is still to be elucidated whether FFRct calculated from the preoperative CCTA data using computational flow dynamics is useful in patients with severe AS who plan to undergo TAVR as a predictor for myocardial ischemia and intraoperative complications.
The objective of this study is to evaluate the relationship between pre-TAVR FFRct and post-TAVR invasive FFR to better understand the impact that non-administration of nitrates has on computed FFR values. In addition, this study also aims to evaluate the relationship between pre- and post-TAVR resting physiology (iFR) and post-TAVR invasive FFR in association with pre- and post-TAVR FFRct to better understand the impact of aortic valve stenosis on the resting coronary physiology.
If the utility of FFRct can be established in patients with severe AS who plan to undergo TAVR based on the results of this research study, the necessity of the intervention in treatment of CAD prior to TAVR and the perioperative risk of TAVR can be evaluated, leading to the marked clinical significance.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
A cut-off value for FFRct that can estimate FFR of <0.80 in patients with severe AS
Key secondary outcomes
(1)A cut-off value for pre-TAVR iFR that can estimate FFR of <0.80 in patients with severe AS
(2)Regression and correlation coefficient of FFRct before TAVR and after TAVR
(3)Regression and correlation coefficient of iFR before TAVR and after TAVR
(4)Stenosis degree in coronary angiography before TAVR predicting FFR: <0.80 in severe AS patients
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Device,equipment |
Interventions/Control_1
The intervention tested in this study is to measure FFR using a guide wire that is capable of sensing pressure following TAVR. After the pressure gradient across the aortic valve is relieved by TAVR, it is considered that FFR can evaluate myocardial ischemia in a safe and accurate manner and can be used as the standard in contrast to pre and post-TAVR FFRct. Another intervention tested in this study is to measure iFR before and after TAVR to assess its potential to accurately estimate myocardial ischemia.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients who meet all the following criteria will be included in the study:
1)Among patients who have undergone CCTA prior to TAVR, those with moderate stenotic lesions (30 to <70%) or severe stenotic lesions on CT who are candidates for PCI following TAVR
2)Patients aged 20 years or older at the time of diagnosis
Key exclusion criteria
Patients who meet any one of the following criteria will be excluded from this study:
1)Patients who were implanted with metal stents in the left main trunk,
2)Patients with stenosis of >30% in the left main trunk who were implanted with at least one metal stent in the vessel(s) of the left coronary circulation,
3)Patients who were implanted with metal stents in at least 2 vessels of the coronary circulation,
4)Patients who requested withdrawal of consent for participation in this research study after providing their consent,
5)Patients who underwent coronary artery bypass surgery,
6)Patients with coronary artery chronic total occlusion,
7)Patients who developed acute myocardial infarction in the past 2 months,
8)Patients whose CCTA was determined to be unreadable during its evaluation at the study site because of the presence of artifacts which were severe enough to cause problems with the angiogram,
9)Patients who were judged by the principal investigator to be unsuitable for the study for other reasons
Target sample size
25
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiromasa Otake |
Organization
Graduate School of Medicine, Kobe University
Division name
Division of Cardiovascular Medicine, Department of Internal Medicine
Zip code
Address
7-5-2 Kusunoki-cho, Chuo-ku, Kobe city, Hyogo
TEL
078-382-5846
hotake@med.kobe-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Ryo Takeshige |
Organization
Graduate School of Medicine, Kobe University
Division name
Division of Cardiovascular Medicine, Department of Internal Medicine
Zip code
Address
7-5-2 Kusunoki-cho, Chuo-ku, Kobe city, Hyogo
TEL
078-382-5846
Homepage URL
takeshige.kobe@gmail.com
Sponsor or person
Institute
Division of Cardiovascular Medicine, Department of Internal Medicine, Graduate School of Medicine, Kobe University
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 09 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2020 | Year | 09 | Month | 01 | Day |
Date of IRB
| 2018 | Year | 10 | Month | 01 | Day |
Anticipated trial start date
| 2018 | Year | 10 | Month | 25 | Day |
Last follow-up date
| 2022 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 07 | Month | 10 | Day |
Last modified on
| 2020 | Year | 01 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038024
